Later, the treatment with either exenatide or liraglutide administered at the time of primary angioplasty in acute myocardial infarction [17, 18] has been consistently proven effective in reducing infarct size by approximately 25% with no effect on LV function, while pre-treatment with i.v. GLP-1 was associated with an improved LV dysfunction during elective angioplasty for single-vessel disease [14]. This evidence concerns the gene GLP1R and myocardial infarction.